{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:30:26Z","timestamp":1768019426721,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Suzhou Industrial Park clinical medical expert team introduction project","award":["0202140004"],"award-info":[{"award-number":["0202140004"]}]},{"name":"Jiangsu Industry University Research Cooperation Project","award":["BY2022855"],"award-info":[{"award-number":["BY2022855"]}]},{"name":"Collaborative innovation research on the combination of medicine and engineering","award":["SZM2023016"],"award-info":[{"award-number":["SZM2023016"]}]},{"name":"Open project of the State Key Laboratory of Radiation Medicine and Protection","award":["GZK1202304"],"award-info":[{"award-number":["GZK1202304"]}]},{"name":"Suzhou Industrial Park Healthcare Talent Support Initiative"},{"name":"Gusu Talent Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05810-2","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:35:30Z","timestamp":1752777330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSA proportion of index lesion: a novel index for predicting prostate pathology outcomes in biopsy-na\u00efve patients with PSA\u2009&lt;\u200910\u00a0ng\/ml and PI-RADS 3 lesions"],"prefix":"10.1007","volume":"43","author":[{"given":"Haojie","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiale","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"1","key":"5810_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"5810_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R et al (2023) Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(10):1067\u20131096","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"5810_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76(3):340\u2013351","journal-title":"Eur Urol"},{"issue":"7","key":"5810_CR4","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00261-023-03929-7","volume":"48","author":"R Nicola","year":"2023","unstructured":"Nicola R, Bittencourt LK (2023) PI-RADS 3 lesions: a critical review and discussion of how to improve management. Abdom Radiol (NY) 48(7):2401\u20132405","journal-title":"Abdom Radiol (NY)"},{"key":"5810_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejrad.2019.02.031","volume":"114","author":"I Hermie","year":"2019","unstructured":"Hermie I, Van Besien J, De Visschere P, Lumen N, Decaestecker K (2019) Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center. Eur J Radiol 114:92\u201398","journal-title":"Eur J Radiol"},{"issue":"10\u201312","key":"5810_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1159\/000534597","volume":"107","author":"Y Cui","year":"2023","unstructured":"Cui Y, Zhao J, Sun Y (2023) The value of the prostate health index and derived indexes in the diagnosis of prostate cancer with PI-RADS-3 lesions. Urol Int 107(10\u201312):959\u2013964","journal-title":"Urol Int"},{"issue":"7","key":"5810_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.urolonc.2020.11.010","volume":"39","author":"L Rico","year":"2021","unstructured":"Rico L, Blas L, Vitagliano G, Contreras P, Rios Pita H, Ameri C (2021) PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? Urol Oncol 39(7):431","journal-title":"Urol Oncol"},{"issue":"2","key":"5810_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s00261-022-03720-0","volume":"48","author":"KC Kortenbach","year":"2023","unstructured":"Kortenbach KC, Logager V, Thomsen HS, Boesen L (2023) Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies. Abdom Radiol (NY) 48(2):688\u2013693","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"5810_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11934-023-01187-0","volume":"24","author":"Z Kang","year":"2023","unstructured":"Kang Z, Margolis DJ, Wang S, Li Q, Song J, Wang L (2023) Management strategy for prostate Imaging Reporting and Data System Category 3 lesions. Curr Urol Rep 24(12):561\u2013570","journal-title":"Curr Urol Rep"},{"issue":"8","key":"5810_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00345-018-2565-3","volume":"37","author":"TJ Kim","year":"2019","unstructured":"Kim TJ, Lee MS, Hwang SI, Lee HJ, Hong SK (2019) Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions. World J Urol 37(8):1581\u20131586","journal-title":"World J Urol"},{"issue":"4","key":"5810_CR11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/jmri.28505","volume":"57","author":"X Li","year":"2023","unstructured":"Li X, Li C, Chen M (2023) Patients with \u201cgray zone\u201d PSA levels: application of prostate MRI and MRS in the diagnosis of prostate cancer. J Magn Reson Imaging 57(4):992\u20131010","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"5810_CR12","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1002\/cam4.5100","volume":"12","author":"C Hu","year":"2023","unstructured":"Hu C, Sun J, Xu Z, Zhang Z, Zhou Q, Xu J et al (2023) Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naive patients with PSA <10 ng\/ml and PI-RADS v2.1 = 3 lesions. Cancer Med 12(3):2560\u20132571","journal-title":"Cancer Med"},{"issue":"3","key":"5810_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G et al (2020) Prostate Imaging Reporting and Data System 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 6(3):463\u2013478","journal-title":"Eur Urol Focus"},{"key":"5810_CR14","doi-asserted-by":"crossref","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. (2020) The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 44(8):e87\u2013e99.","DOI":"10.1097\/PAS.0000000000001497"},{"issue":"5","key":"5810_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/jmri.24985","volume":"42","author":"AB Rosenkrantz","year":"2015","unstructured":"Rosenkrantz AB, Padhani AR, Chenevert TL, Koh DM, De Keyzer F, Taouli B et al (2015) Body diffusion kurtosis imaging: basic principles, applications, and considerations for clinical practice. J Magn Reson Imaging 42(5):1190\u20131202","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"5810_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S et al (2012) 3D Slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging 30(9):1323\u20131341","journal-title":"Magn Reson Imaging"},{"issue":"21","key":"5810_CR17","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77(21):e104\u2013e107","journal-title":"Cancer Res"},{"issue":"2","key":"5810_CR18","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1111\/ajco.13347","volume":"17","author":"G Sonmez","year":"2021","unstructured":"Sonmez G, Tombul ST, Demirtas T, Demirtas A (2021) Clinical factors for predicting malignancy in patients with PSA < 10 ng\/mL and PI-RADS 3 lesions. Asia Pac J Clin Oncol 17(2):e94\u2013e99","journal-title":"Asia Pac J Clin Oncol"},{"key":"5810_CR19","doi-asserted-by":"publisher","first-page":"1500010","DOI":"10.3389\/fonc.2024.1500010","volume":"14","author":"JG Chai","year":"2024","unstructured":"Chai JG, Li YH, Ke CX (2024) Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng\/ml and PI-RADS <\/= 3 lesions. Front Oncol 14:1500010","journal-title":"Front Oncol"},{"issue":"2","key":"5810_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","volume":"86","author":"F Moller","year":"2024","unstructured":"Moller F, Mansson M, Wallstrom J, Hellstrom M, Hugosson J, Arnsrud GR (2024) Prostate cancers in the prostate-specific antigen interval of 1.8\u20133 ng\/ml: results from the Goteborg-2 prostate cancer screening trial. Eur Urol 86(2):95\u2013100","journal-title":"Eur Urol"},{"issue":"18","key":"5810_CR21","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1002\/cncr.34355","volume":"128","author":"AM Fang","year":"2022","unstructured":"Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G et al (2022) Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer 128(18):3287\u20133296","journal-title":"Cancer"},{"issue":"8","key":"5810_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.urolonc.2023.05.005","volume":"41","author":"TA Nguyen","year":"2023","unstructured":"Nguyen TA, Fourcade A, Zambon A, Saout K, Deruelle C, Joulin V et al (2023) Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI. Urol Oncol 41(8):354","journal-title":"Urol Oncol"},{"issue":"5","key":"5810_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/cancers17050753","volume":"17","author":"H Kamecki","year":"2025","unstructured":"Kamecki H, Tokarczyk A, Debowska M, Bialonczyk U, Malewski W, Szostek P et al (2025) A simple nomogram to predict clinically significant prostate cancer at MRI-guided biopsy in patients with mild PSA elevation and normal DRE. Cancers (Basel) 17(5):753","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5810_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ et al (2016) PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 69(1):16\u201340","journal-title":"Eur Urol"},{"issue":"11","key":"5810_CR25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.urolonc.2022.08.003","volume":"40","author":"J Drevik","year":"2022","unstructured":"Drevik J, Dalimov Z, Uzzo R, Danella J, Guzzo T, Belkoff L et al (2022) Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative. Urol Oncol 40(11):490","journal-title":"Urol Oncol"},{"issue":"1","key":"5810_CR26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41598-020-78428-6","volume":"11","author":"YH Fan","year":"2021","unstructured":"Fan YH, Pan PH, Cheng WM, Wang HK, Shen SH, Liu HT et al (2021) The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. Sci Rep 11(1):1286","journal-title":"Sci Rep"},{"issue":"1","key":"5810_CR27","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1038\/s41598-024-57337-y","volume":"14","author":"J Wen","year":"2024","unstructured":"Wen J, Liu W, Shen X, Hu W (2024) PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4\u201310 ng\/ml. Sci Rep 14(1):6570","journal-title":"Sci Rep"},{"issue":"1","key":"5810_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12880-017-0184-x","volume":"17","author":"XK Niu","year":"2017","unstructured":"Niu XK, Li J, Das SK, Xiong Y, Yang CB, Peng T (2017) Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone. BMC Med Imaging 17(1):11","journal-title":"BMC Med Imaging"},{"issue":"17","key":"5810_CR29","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.3390\/cancers16173084","volume":"16","author":"F Palmisano","year":"2024","unstructured":"Palmisano F, Lorusso V, Legnani R, Martorello V, Nedbal C, Tramanzoli P et al (2024) Analysis of the performance and accuracy of a PSA and PSA ratio-based nomogram to predict the probability of prostate cancer in a cohort of patients with PIRADS 3 findings at multiparametric magnetic resonance imaging. Cancers (Basel) 16(17):3084","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5810_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-024-06949-7","volume":"52","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang J, Xiao L, Zhou M, Cai Y et al (2025) Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS <\/= 3 MRI. Eur J Nucl Med Mol Imaging 52(3):913\u2013924","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5810_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/pros.24840","volume":"85","author":"A Ayranci","year":"2025","unstructured":"Ayranci A, Caglar U, Yazili HB, Erdal FS, Erbin A, Sarilar O et al (2025) PSA Density and lesion volume: key factors in avoiding unnecessary biopsies for PI-RADS 3 lesions. Prostate 85(4):385\u2013390","journal-title":"Prostate"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05810-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05810-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:02:48Z","timestamp":1767996168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05810-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5810"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05810-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective observational study was conducted in accordance with the Declaration of Helsinki and was reviewed and approved by the Ethics Committee\/Institutional Review Board of our hospital (Approval Number: 251163, Approval Date: 2025\/1\/12). As this study involved the analysis of existing, anonymized medical data collected during routine clinical care prior to the initiation of this research, and given the retrospective nature and large cohort size, obtaining individual written informed consent from each participant was waived by the approving Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement and Consent to Participate"}}],"article-number":"444"}}